Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
Recruiting
This is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group, dose-ranging study, conducted in subjects with moderate-to-severe atopic dermatitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/04/2022
Locations: AkesoBio Investigative Site 2022, Ridgeland, Mississippi
Conditions: Atopic Dermatitis